Recent Developments
Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded Gelteq® technology (a delivery technology) applications, and advanced toward future clinical milestones including:
| ● | Human clinical trial planning completed and the clinical trial is expected to commence next quarter (beginning July 1, 2026), which can potentially advance Gelteq’s pharmaceutical program toward a potential FDA regulatory pathway; |
| ● | Veterinary clinical trial commenced for an antiparasitic drug candidate, supporting a planned FDA application targeted for later in 2026 in a global animal health market estimated to exceed US$78 billion1; |
| ● | Preclinical diabetes study commenced, expanding the pharmaceutical pipeline into a major chronic-disease category; |
| ● | Development underway in our research facilities to incorporate peptides and peptide-based therapeutics into stable oral formulations, spanning compounds traditionally delivered by injection and an emerging generation of therapies in development; |
| ● | Signed a strategic debt financing of up to US$3.5 million with an institutional investor to advance our clinical programs and accelerate commercialization; |
| ● | Veterinary palatability trials with Kemin Industries completed, with trial results demonstrating strong canine acceptance and confirming Gelteq’s ability to mask bitter functional ingredients; |
| ● | Commercial product manufactured for a new customer in the East Asian region, demonstrating Gelteq’s ability to formulate, manufacture and deliver at commercial scale; |
| ● | Center of Excellence established in Guangdong Province, China, providing strategic access to one of the world’s fastest-growing pharmaceutical ecosystems; and |
| ● | Continued expansion of API pipelines across multiple therapeutic categories. |
References
| 1 | Fortune Business Insights. (2025). Animal health market size, share & industry analysis. Report ID: FBI102371 |
